Aflatoxin B1: from metabolism to multi-organ carcinogenesis
4 affiliations
- 1The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan 232001, China
- 2College of Public Health, Anhui University of Science and Technology, Hefei 230000, China
- 3Joint Research Center of Occupational Medicine and Health, Institute of Grand Health, Hefei Comprehensive National Science Center, Hefei 230000, China
- 4College of Life and Health, West Anhui University, Luan, Anhui, China
Abstract
Aflatoxin B1 (AFB1), a Group 1 carcinogen classified by the International Agency for Research on Cancer, chronically exposes a substantial proportion of the global population through dietary intake, primarily from fungal contamination of staple crops such as maize and peanuts. Climate change is progressively expanding this problem beyond its traditional tropical and subtropical boundaries into temperate regions of Europe and Asia. The carcinogenicity of AFB1 is initiated by its metabolic activation via hepatic cytochrome P450 enzymes, yielding AFBO, which forms DNA adducts and subsequently induces the signature G-to-T transversion mutation at codon 249 of TP53. However, recent evidence indicates that this canonical pathway represents only part of a far more complex picture. This review advances three interconnected themes. First, the aryl hydrocarbon receptor (AHR) has been established as an upstream regulatory hub of AFB1 toxicity, both driving CYP-mediated metabolic activation and mediating PD-L1 upregulation to promote immune evasion. Second, oxidative stress, epigenetic reprogramming, and autophagic dysfunction operate as accelerators that drive malignant transformation. Third, the multi-organ toxicity of AFB1, encompassing intestinal barrier disruption, systemic immunosuppression, and renal and reproductive toxicity, together with its co-exposure with hepatitis B virus and other mycotoxins, is expanding our traditional understanding of synergistic carcinogenesis. On the translational front, this review integrates the biomarker continuum from exposure (AFB1-albumin adducts) through effect (TP53 mutation, epigenetic marks) to susceptibility (GST/CYP genotypes, GNMT, CDKN2A), and synthesizes a multi-tiered intervention framework spanning source control, chemoprevention (AHR inhibitors, antioxidants), microbial/enzymatic detoxification, and precision immunotherapy (Figure 1(Fig. 1)).
Related
- Understanding the biological processes of kidney carcinogenesis: an integrative multi-omics approach
- Multi-trait selection of tropical maize hybrids for combined productivity, agronomic stability, and aflatoxin resistance
- Long Noncoding RNA PCALRx Interacts with Pyruvate Carboxylase to Drive Multi‐Organ Developmental Toxicity in Zebrafish Embryos Exposed to Amoxicillin
- Chemically modified CRISPR enzymes for multi-organ genome editing in vivo
- Intercellular communication and multi-organ axis interactions in the pathogenesis of MASLD: a signal-class synthesis graded by disease context and causal status
BibTeX
@article{yu2026aflatoxin,
title = {{Aflatoxin B1: from metabolism to multi-organ carcinogenesis}},
author = {Pan Yu and Jiacheng Li and Weiya Cao and Yongchang Cao and Wenhui Lv and Hanxu Wang and Jiaxiang Zhang and Xiaoyu Bai and Shuhui Feng},
journal = {EXCLI Journal},
year = {2026},
month = oct,
doi = {10.17179/excli2026-9793},
url = {https://doi.org/10.17179/excli2026-9793},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Aflatoxin B1: from metabolism to multi-organ carcinogenesis
AU - Pan Yu
AU - Jiacheng Li
AU - Weiya Cao
AU - Yongchang Cao
AU - Wenhui Lv
AU - Hanxu Wang
AU - Jiaxiang Zhang
AU - Xiaoyu Bai
AU - Shuhui Feng
PY - 2026
DA - 2026/10/05
JO - EXCLI Journal
DO - 10.17179/excli2026-9793
UR - https://doi.org/10.17179/excli2026-9793
AB - Aflatoxin B1 (AFB1), a Group 1 carcinogen classified by the International Agency for Research on Cancer, chronically exposes a substantial proportion of the global population through dietary intake, primarily from fungal contamination of staple crops such as maize and peanuts. Climate change is progressively expanding this problem beyond its traditional tropical and subtropical boundaries into temperate regions of Europe and Asia. The carcinogenicity of AFB1 is initiated by its metabolic activation via hepatic cytochrome P450 enzymes, yielding AFBO, which forms DNA adducts and subsequently induces the signature G-to-T transversion mutation at codon 249 of TP53. However, recent evidence indicates that this canonical pathway represents only part of a far more complex picture. This review advances three interconnected themes. First, the aryl hydrocarbon receptor (AHR) has been established as an upstream regulatory hub of AFB1 toxicity, both driving CYP-mediated metabolic activation and mediating PD-L1 upregulation to promote immune evasion. Second, oxidative stress, epigenetic reprogramming, and autophagic dysfunction operate as accelerators that drive malignant transformation. Third, the multi-organ toxicity of AFB1, encompassing intestinal barrier disruption, systemic immunosuppression, and renal and reproductive toxicity, together with its co-exposure with hepatitis B virus and other mycotoxins, is expanding our traditional understanding of synergistic carcinogenesis. On the translational front, this review integrates the biomarker continuum from exposure (AFB1-albumin adducts) through effect (TP53 mutation, epigenetic marks) to susceptibility (GST/CYP genotypes, GNMT, CDKN2A), and synthesizes a multi-tiered intervention framework spanning source control, chemoprevention (AHR inhibitors, antioxidants), microbial/enzymatic detoxification, and precision immunotherapy (Figure 1(Fig. 1)).
SN - 1611-2156
ER -